The overall objective of this contract is to advance the development of monovalent vaccines for prevention of marburg virus (marv) and sudan ebolavirus (sudv) disease. These vaccines are based on…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50121C00077
- Awardee
-
International Aids Vaccine Initiative Inc. UEI ZEJBC8JQM3P5
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $95,592,504
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Pre-Solicitation · BAA18100SOL00003 · Posted Oct 16, 2017
- Contract value 57% obligated
-
- $95,592,504.00 Current, with exercised options
- $166,898,763.00 Potential, with all options
- Completion date 70% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- New York, NY 10004, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $1,556,355 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $18,315,722 | |
| Exercise an Option | $29,796,349 | |
| Exercise an Option | $17,187,061 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $28,737,017 |
Show all 11
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a $166.898 million definitive contract to International AIDS Vaccine Initiative Inc. for the advanced development of monovalent vaccines for prevention of Marburg Virus and Sudan Ebolavirus on September 30, 2021, with performance extending through December 31, 2028.
The contract advances vaccine candidates based on recombinant expression of filovirus glycoproteins. Place of performance is New York, NY 10004. The originating solicitation was a Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement posted October 16, 2017, seeking proposals for advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear and pandemic influenza threats, with multiple awards anticipated in the $750,000 to $8 million range. This award substantially exceeds that range, reflecting scope and technical advancement.
The contract employs a firm fixed-price structure. In FY2022, the contract invoiced $3 million across 5.0 FTEs and 10,401 contractor hours, yielding a derived government-paid rate of $291.44 per hour. Subcontractors performed 22 percent of contractor hours, with four named subs engaged in that fiscal year.
The prime subcontractor portfolio includes Fisher Bioservices Inc. (clinical trials division and parent entity Fisher Clinical Services Inc.) providing cold-chain storage, handling, and distribution of drug products and diluents; Batavia Biosciences Inc. providing viral seed generation, process optimization, GMP manufacturing, and stability studies; Brigham & Women's Hospital providing Phase 1 clinical trial administration; Johnson County Clintrials LLC providing Phase 1 Ebola Sudan and Marburg clinical trial services; George Washington University providing Phase 1 clinical trial coordination; PPD Development LP providing clinical trial monitoring; The Emmes Company providing biostatistical analysis and clinical data management; La Jolla Institute for Immunology providing immunological assessment; Advarra Inc. providing IRB and IBC oversight; and Battelle Memorial Institute providing analytical assay support for vaccine development.
Description
The overall objective of this contract is to advance the development of monovalent vaccines for prevention of marburg virus (marv) and sudan ebolavirus (sudv) disease. These vaccines are based on recombinant expression of filovirus glycoproteins in
Subawards
Show all 36
Quick answers
Who was awarded contract 75A50121C00077?
75A50121C00077 was awarded to International Aids Vaccine Initiative Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2021.
How much is contract 75A50121C00077 worth?
The government has obligated $95,592,504 on 75A50121C00077. Its potential value, with all options, is $166,898,763.
Was contract 75A50121C00077 competed?
The extent of competition for 75A50121C00077 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award